DALLAS, Nov. 27, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Puration, Inc. (USOTC: PURA) and Kali, Inc. (USOTC: KALY) today announced a letter to shareholders from the incoming CEO of Kali, Frederick Ferri, in conjunction with the recent acquisition of his company NCM Biotech by Kali, in addition to addressing how Kali fits into Puration’s recent announcement with Generex (USOTC: GNBT).  Puration yesterday announced an agreement with Generex Biotechnology Corporation to develop and produce NuGenerex CBD HydroHealth High Alkaline Water.  The Puration and Generex announcement detailed the agreement as part of a larger developing agreement with US Cannabis Health.  Puration is a partner in US Cannabis Health with Kali and Nouveau Life Pharmaceuticals (USOTC: NOUV).  Mr. Ferri’s letter provides more detail on the value Kali brings to the Puration and Generex agreement to develop and produce NuGenerex CBD HydroHealth High Alkaline Water.  The letter is included in its entirety below:

Dear Kali Shareholders –

I’m delighted to be joining you in taking Kali in a new direction.  I’ve been working for years now in developing the science behind a cannabis extraction process in addition to working on applications for the extracts from that process.  As you likely already know by now, the extraction process has been patented.  However, you are likely less familiar with the research that has been conducted with various extracts derived from the patented process.  Over the coming months you will have the opportunity to learn a good deal about the research.  You can expect to soon see the publication of research based on the application of extracts from the patented process in the treatment of specific conditions and diseases.  In the meantime, I encourage you to visit the new Kali website my team has built to keep shareholders up to date on our latest developments.  The website is brand new and a work in progress, so check back frequently.  In particular, please take time to review the section on Kali’s new business plan in conjunction with the recent acquisition of NCM Biotech, the company I founded:

https://www.kali-extracts.com/kaliextract-biz-plan/

The announcement yesterday between Puration and Generex is very exciting for Kali.  Let me explain why.  First, you need to know that Puration is the only licensee of what is now Kali’s patented cannabis extraction process.  Puration has licensed the patent for specific, non-pharmaceutical applications.  In conjunction with their license, Puration has been very successful in developing and marketing a CBD infused bottled water called EVERx CBD Sports Water.  Second, you need to know that Puration and Kali have formed a joint venture company called US Cannabis Health for the purpose of developing and marketing pharmaceutical applications and non-pharmaceutical wellness concentrates derived from Kali’s patented extraction process.  Now understanding the relationship between Puration and Kali, know that the announcement yesterday about the agreement between Puration and Generex was part of a larger agreement executed between Generex and US Cannabis Health.  While Puration will be producing the NuGenerex CBD HydroHealth High Alkaline Water, Kali will be developing custom CBD extracts for Puration to infuse into the NuGenerex CBD HydroHealth High Alkaline Water.

With the patented extraction process now under the Kali banner, we have already developed and tested a number of different extracts as therapies for symptoms of specific health issues.  We have accordingly already initiated the process of filing for new patents in conjunction with our research.  With the Generex agreement announced yesterday, we will refine our existing research to specifically target Generex’s purposes and correspondingly file additional patent applications on behalf of Kali, Puration, US Cannabis Health and Generex.

I anticipate that with my letter today, you now have a better understanding of why I am so excited for Kali and its shareholders about the announcement yesterday by Puration and Generex.  I think the Puration and Generex shareholders should be equally excited.  I am thoroughly familiar with all of the current cannabis extraction science in the market place and I contend that our technology is a standout.  I am confident the NuGenerex CBD HydroHealth High Alkaline Water will be a big success.  I am even more excited by what I believe this first step with Generex will lead to in regard to pharmaceutical applications derived from Kali’s patented extract process.

Sincerely,
Frederick Ferri

To learn more about Kali, visit www.kali-extracts.com

To learn more about Puration, visit www.purationinc.com

Disclaimer/Safe Harbor: 

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Kali, Inc.
Frederick Ferri
ir@kali-extracts.com
214 210-0459

Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.